Indianapolis
-
Elli Lilly Cancer Drug Lands Its Second FDA Approval This Year
Eli Lilly’s Jaypirca is now approved for treating three types of blood cancers. While Jaypirca blocks a target already addressed by other cancer therapies, the Lilly molecule does it in a way that sets it apart from the rest of its drug class.
-
FDA Approves Eli Lilly Weight Drug, Now Set to Compete Against Novo’s Wegovy
Eli Lilly weight management drug Zepbound landed its much anticipated FDA approval. The new Lilly product is in the same drug class as Novo Nordisk weight medication Wegovy, but it offers an additional mechanism of action and costs less.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Eli Lilly Strikes $250M Deal to Add Gene-Editing Medicines for Cardio Conditions
Eli Lilly is acquiring Beam Therapeutics’ opt-in rights to three Verve Therapeutics gene-editing therapies for cardiovascular conditions. The deal comes four months after the pharmaceutical giant began a partnership on a preclinical Verve gene-editing therapy for a different target.
-
Eli Lilly Jumps Into Radiopharmaceuticals via $1.4B Point Biopharma Acquisition
Acquiring Point Biopharma gives Eli Lilly a pipeline of radiopharmaceuticals, including one for prostate cancer that could rival Novartis’s Pluvicto. The deal comes ahead of an expected Phase 3 data readout for that Point therapeutic candidate.
-
Eli Lilly Strengthens the Case for Going Early in Alzheimer’s Treatment
Alzheimer’s disease patients in the earliest stages of their disease benefited the most from Eli Lilly drug donanemab, which is expected to receive an FDA decision by the end of 2023. Full results from the drug’s pivotal study were presented during the during the Alzheimer’s Association International Conference.
-
Eli Lilly to Buy Sigilon, Betting the Biotech Can Overcome a Cell Therapy Limitation
Eli Lilly is expanding its diabetes prospects by acquiring cell therapy developer Sigilon Therapeutics. The two companies are already partners in the development of a type 1 diabetes cell therapy currently in preclinical development.
-
Eli Lilly’s Triple Mechanism Sets New High Mark for Weight Loss Drugs
Eli Lilly’s retatrutide led to an average weight reduction of 24.2%, or 58 pounds, after 48 weeks of treatment in Phase 2 testing. Based on these results, Lilly now plans a comprehensive Phase 3 program that will evaluate the once-weekly injectable drug in weight reduction as well as various complications of obesity.
-
Eli Lilly Bets $2.4B on Dice Therapeutics’ Oral Drugs for Psoriasis and More
Eli Lilly’s acquisition of Dice Therapeutics comes eight months after the biotech reported positive data from a Phase 1 study in psoriasis. Dice develops oral small molecule drugs intended to offer alternatives to biologic drugs that are injected or infused.
-
Eli Lilly Puts Up $60M for In Vivo Gene-Editing Med for Cardiovascular Disease
Eli Lilly’s partnership with Verve Therapeutics covers the development of a preclinical therapy addressing a protein associated with cardiovascular disease risk. The in vivo gene-editing therapy is a potential one-time treatment.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Eli Lilly Alzheimer’s Drug Meets Phase 3 Goals, Teeing Up Plans for FDA Filing
Patients treated with Eli Lilly Alzheimer’s disease drug donanemab showed a 35% slowing in decline compared to those given a placebo. Based on the Phase 3 results, Lilly said it would seek FDA approval for the drug by the end of June.
-
Eli Lilly Unloads Emergency Nasal Spray Diabetes Drug for $500M Up Front
Eli Lilly is selling to Amphastar Pharmaceuticals global rights to Baqsimi, an emergency treatment for severe hypoglycemia in diabetes patients. The deal come as Lilly turns its focus to novel medicines for diabetes and other indications.
-
FDA Rejects Eli Lilly Ulcerative Colitis Drug Over Manufacturing Issues
Rejection of Eli Lilly’s mirikizumab means that two of the four drugs the pharma giant identified as revenue growth drivers for 2023 have failed to pass the regulatory bar. One of those drugs has been approved while the fourth drug still awaits an FDA decision.
-
Eli Lilly Places a Small Bet on Confo’s Early-Stage, Non-Opioid Pain Drug
Eli Lilly is paying $40 million up front for rights to a Confo Therapeutics drug in Phase 1 testing as a potential treatment for neuropathic pain. Confo develops drugs that target G-protein coupled receptors.
-
Eli Lilly’s Insulin: Cheaper for Patients Without Much Financial Hit to the Firm
Eli Lilly is slashing prices for its insulin products and capping a patient’s monthly out-of-pocket costs at $35. But a financial analyst notes that the company can afford to cut prices on older medicines like insulin because the strategy will help it maintain pricing power for innovative new drugs.
-
Eli Lilly Turns to Startup Capsida to Bring Gene Therapy Into the Brain
Eli Lilly is paying $55 million up front to begin an alliance with Capsida Biotherapeutics pursuing gene therapies for central nervous system disorders. Capsida’s technology enables the delivery of a gene therapy to a single organ or multiple organs, a capability that could bring such treatments to a wider range of diseases.